The Food and Drug Administration approved Sientra Inc.'s (Nasdaq: SIEN) PMA supplemental allowing commercialization of its OPUS-branded breast implant products lifting the stock price 93 cents to close at $11.98.
FDA approves Sentra's PMA supplemental
April 19, 2018 at 16:47 PM EDT
